Eli Lil­ly's Taltz beats J&J's Trem­fya in pso­ri­a­sis head-to-head — but the mar­ket­ing brawl is just be­gin­ning

Eli Lil­ly has come out swing­ing at J&J, stak­ing out its chal­lenger po­si­tion in a crowd­ed bat­tle of plaque pso­ri­a­sis block­busters.

In a Phase IV head-to-head study with 1,027 pa­tients, Lil­ly says its IL-17A in­hibitor Taltz beat J&J’s IL-23/p19 drug Trem­fya on com­plete skin clear­ance at week 12 as de­fined by PASI 100. It’s the first di­rect com­par­i­son of these two class­es us­ing PASI 100 as a pri­ma­ry end­point, Lil­ly says, though it al­so shows that Taltz is con­sis­tent­ly su­pe­ri­or in mea­sures of PASI 50, PASI 75 and PASI 90 at mul­ti­ple (al­though not all) time points — com­pris­ing a num­ber of “key sec­ondary end­points.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.